Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Stable isotope tracer (13-C(4)-BHB)
Stable isotope tracer · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Biomarker evaluation |
| Name | Type | Description |
|---|---|---|
| Stable isotope tracer (13-C(4)-BHB) | DRUG | A stable isotope tracer (13-C(4)-BHB), a commercially available lipid emulsion, and heparin will be administered intravenously. Ketone body concentrations will be measured before beginning the infusion, at approx. 135 minutes, and at approx. 255 minutes. |
Inclusion Criteria: * Subject has a Body Mass Index of 18-25 kg/m2 OR 29-40 kg/m2 * Subject has been a nonsmoker or has not used nicotine for the past 6 months Exclusion Criteria: * Subject has a history of diabetes mellitus * Subject has a history of stroke, chronic seizures, or other neurologic...
The stable isotope tracer (13-C(4)-BHB) is a small molecule being developed by Merck & Company, Inc. (MRK) for diabetes. It is a Phase 1 metabolic agent studied as a pharmacodynamic marker of hepatic fatty acid oxidation. It is also known as 13-C(4)-BHB.
Merck & Company, Inc. (MRK) is developing the stable isotope tracer (13-C(4)-BHB). The company is the sponsor of the Phase 1 trial evaluating the tracer in diabetes.
The stable isotope tracer (13-C(4)-BHB) is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. One Phase 1 trial has been completed.
The stable isotope tracer (13-C(4)-BHB) was studied in a completed Phase 1 trial, NCT00860392, titled 'A Comparison of Measurements of Ketone Body Flux Versus Ketone Body Concentration as a Pharmacodynamic Marker of Hepatic Fatty Acid Oxidation (0000-110).' The trial enrolled 24 healthy male volunteers aged 18 years and older and was conducted in diabetes.
Yes, the stable isotope tracer is also known as 13-C(4)-BHB. Both names refer to the same Merck & Company, Inc. (MRK) Phase 1 small molecule being studied in diabetes.